期刊
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
卷 112, 期 6, 页码 302-311出版社
ELSEVIER TAIWAN
DOI: 10.1016/j.jfma.2013.02.001
关键词
antiviral therapy; chronic hepatitis B; hepatitis B virus DNA; nucleos(t)ide analogs; pegylated interferon; quantitative HBsAg
资金
- National Taiwan University Hospital
- Department of Heath
- National Science Council, Executive Yuan, Taiwan
Baseline and on-treatment hepatitis B viral factors are reported to affect treatment responses. A lower baseline hepatitis B virus (HBV) DNA level is a strong predictor of the response to antiviral therapy. HBV genotype A/B patients have better responses to interferon-based therapy than those with genotypes C/D. Regarding the association of HBV mutants with responses to antiviral therapy, current evidence is limited. On-treatment viral suppression is the most important predictor of response to nucleoside analogs. On-treatment hepatitis B surface antigen decline is significantly associated with response to pegylated interferon. In the future, individualized therapy should be based on treatment efficacy, adverse effects, baseline and on-treatment predictors of antiviral therapy. Copyright (C) 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据